The Scottish Medicines Consortium (SMC) has recommended GlaxoSmithKline’s (GSK) Anoro Ellipta 52/22mcg (umeclidinium / vilanterol), a new once-daily dual bronchodilator treatment for chronic obstructive pulmonary disease (COPD).
SMC has recommended Anoro for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD within NHS Scotland.
GSK UK medical director Dr Stephen McDonough said: "COPD causes permanent damage to the airways and can cause significant distress to the thousands of people living with the condition in Scotland.
"This new dual bronchodilator offers clinicians a new option to help better tailor treatment approaches to individual patients and their symptom management."
With the positive advice, GSK will supply the drug to health boards across Scotland, allowing appropriate patients with COPD access to a combination of two bronchodilators in a single dry powder inhaler, the Ellipta.
Anoro includes muscarinic antagonist (LAMA) umeclidinium and beta2agonist (LABA), which will relax airway muscles and improve airflow in and out of the lungs.
The decision was based on the launch of Anoro in the UK in September 2014 and European Commission’s marketing authorisation approval in May 2014.
According to SMC, two randomised controlled studies demonstrated that after 24 weeks of treatment, umeclidinium/vilanterol significantly improved lung function compared against an inhaled long-acting muscarinic antagonist in patients with moderate to very severe COPD.
Indirect comparisons showed comparable efficacy with other combinations of long acting muscarinic antagonist plus long acting beta agonist, noted SMC.
Image: A chest X-ray demonstrating severe COPD. Photo: courtesy of James Heilman, MD.